Merck Executives Upbeat on Terns’ Leukemia Drug After Study Data Release

Merck executives maintain a positive outlook for Terns’ leukemia drug, despite recent study data suggesting the treatment may not be as unique as initially hoped. Executives made the claims Thursday during an earnings call.

The company’s optimism persists even with updated study data that indicates Terns’ treatment might offer less differentiation than previously anticipated. However, executives stated that the drug still represents a potentially significant advancement in leukemia care.
n

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 30, 2026

Author

GOAI